ClinicalTrials.gg
Not yet recruitingNCT07069231Updated Jul 16, 2025

Effect of Bio-activation on Epithelial and Connective Cell Adhesion to Titanium Abutments: Split Mouth Clinical Trial

An interventional study of the test group were placed in an Argon plasma reactor in Missing Tooth/Teeth, sponsored by Universita degli Studi di Genova. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Universita degli Studi di Genova · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

The aim of this "in vivo" controlled trial is to assess soft tissue cell adhesion to titanium abutments subjected to different cleaning procedures - no treatment (as they come from the industry), and cleaning by plasma- at an early healing time.

In fact, the primary aim is Quantity and Quality of soft tissue adhesion at the microscopic level (e.g Fibronectin, Integrin-actin).

The secondary Aim - Clinical parameters and outcomes - BOP, PPD, MBL (Marginal Bone Level to check influence of plasmapp-treated abutments).

The null hypothesis of the study was that the cleaning procedure applied to implant abutments has no effect on soft tissue cell adhesion and MBL at an early healing time.

02

Conditions studied

  • Missing Tooth/Teeth
03

In context

Lead sponsor

Universita degli Studi di Genova is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • presence of at least 4 mm of keratinized mucosa around the implants,
  • patients aged 18 years or older
  • medically healthy patients (), or patients with mild systemic disease (ASA II)
  • Total or partial edentulous state with space for at least 2 implants

Exclusion criteria

Exclusion Criteria:

  • 3
  • severe smokers (> 10 cig/day)
  • patients undergoing bisphosphonate therapy
  • pregnant or lactating women
  • estrogen-related hormonal disorders or hormonal substitution therapy patients with a history of head and neck cancers and radiotherapy in this region
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Machined Abutment - control

    The control group received MUA without plasma treatment.

  • Experimental
    Plasma abutment - test

    .The MUA allocated to the test group will be placed in a plasma reactor (Plasmapp, South Korea) for decontamination and activation of the surface. In order to restrict any post-treatment contamination; abutments will be inserted immediately after the end of the plasma process.

    Device: the test group were placed in an Argon plasma reactor

Interventions

  • Devicethe test group were placed in an Argon plasma reactor

    the test group were placed in an Argon plasma reactor

06

What researchers measure

Primary outcomes

  1. connective tissue coverage

    • Coverage was defined as the extent to which the abutment surface was occupied by adherent cells. It reflects the spatial distribution of cells across the surface, providing a measure of surface colonization. Coverage was independently scored on a scale from 1 to 10 by two blinded operators who were unaware of the sample group assignments (i.e., activated vs control). The individual scores were subsequently averaged to obtain a representative value for each parameter per sample.

    Time frame: 3 months post-op

Secondary outcomes

  1. Connective tissue density

    • Density was defined as the degree of cellular accumulation in the regions where cells were present. This parameter reflects the local compactness of cells, irrespective of how widely they are spread across the surface. Density was independently scored on a scale from 1 to 10 by two blinded operators who were unaware of the sample group assignments (i.e., activated vs control). The individual scores were subsequently averaged to obtain a representative value for each parameter per sample.

    Time frame: 3 months post-op

  2. Mean bon loss

    MBL will be measured at 1-year follow up using orthopanoramic or endo-oral Xray.

    Time frame: 1 year post-op

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Canullo L, Donato A, Savadori P, Radovanovic S, Iacono R, Rakic M. Effect of argon plasma abutment activation on soft tissue healing: RCT with histological assessment. Clin Implant Dent Relat Res. 2024 Feb;26(1):226-236. doi: 10.1111/cid.13286. Epub 2023 Oct 18. PubMed 37853303 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Oct 2025, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2025
First posted
Jul 16, 2025
StartEst.
Jul 15, 2025
Primary completionEst.
Oct 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07069231
Lead sponsor
Universita degli Studi di Genova
Responsible party
Paolo Pesce (Prof., Universita degli Studi di Genova) — Principal investigator
First posted
Jul 16, 2025
Start date
Jul 15, 2025 (estimated)
Primary completion
Oct 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Jul 16, 2025

Study contacts

Luigi Canullo
Contact
luigicanullo@yahoo.com
+39393476201976‬

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion